Member Info for Utahsaints

Ahf etc

If we do not see the price rise as everyone is expecting come June, what are your predictions gogin forward? Will you be just as bullish or slightly concerned?

Thoth if you look at it's price now I think the test will be when to sell out because it's share is now slot closer to to $100m valuation so big rise big fall. Personally I would like that choice taken from me and sareum just sells out completely

no its not, your link shows there is a posting about every 2 weeks or so? Hardly a lot of chat

Still one of my favourite bands especially like Do nothing. I even liked fun boy three. I used to learn all the words as a kid especially to too much too youn

Ahfam tbf that's always your standard answer and to date it's not happened. I do appreciate your dedication and your postings though

Ahf
I wager you now that our valuation will not be $2bn by may or June. We are as thoth said xxx poor in that area

Why would we want to do a deal with a company worth only $2b? It will mean some kids nd of payment in shares surely .

Zentalis valuation is 2bn ?

I think people are post fatigue or just that we may as well hibernate for May

cheers Ahf

i see your thinking and why you are so bullish

Any deals brokered ? That's the missing part I was hoping Ahf could complete

Hi Ahfam

explain this to me please

Dr Michael Owen, aged 67, has worked in biomedical research, and in the pharmaceutical and biotechnology industries for nearly 40 years. He is the co-founder and first CSO of Kymab Ltd, a biopharmaceutical company based in Cambridge, UK, prior to which he worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D. Dr Owen currently serves on the boards of several public and private biotechnology companies in the UK, Europe and the USA, including Avacta Group plc, ReNeuron plc, GammaDelta Therapeutics and Zealand Pharma A/S. He is also the Chairman of Ossianix Inc. In addition, Dr Owen is Chairman of ReNeuron’s and Avacta’s scientific advisory boards, an advisor to Abingworth LLP and was until recently an advisor to the CRT Pioneer Fund. Dr Owen received a MA from Oxford University and a PhD from Cambridge University, and is an elected member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.

Working if we combine the 2 then we would be 10 times what we are
Just a reminder what sareum
development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
The last part is all I care about

It seems only sareum can do a presentation and the price drops!
I can never work it out. Hopefully a quick turnaround tomorrow

I have price dropping, is that not happening ?

5p by June seems quite conservative to me, im thinking with a little bit of encouragement 5p by mid May and then a continuous rise to June to say 7p. If we are confident of what we have 10p by June is an easy target

I know what you are saying potnak but if we did see the same kind of rises then we are talking about apric of 15p to 20p for sar and I think most would take that. Let's see how it pans out but this has to be the year that at least 10p is achieved considering all the potential

Cheers stoney. I will wait for sareum to get their pr back side into gear

Are people that we have something to do with the pfizer testing or is it a case that we are having something similar being tested ?

I would say there are a couple of moles in this camp given how the the price rises and falls. I think some lth who seem positive are actually trading a bit